Biomass
$1
+0%
Broad Spectrum Distillate
$3,674
+0%
CBD Isolate
$1,157
-16%
CBG Isolate
$7,408
-1.8%
Hemp Seed Oil
$109
+0%
MCT Oil
$109
+0%
Water Soluble CBD
$2,373
-0.7%
Back to news
18. May 2020
Market Watch Medical News Pharmaceutical United Kingdom

Khiron Receives First Medical Cannabis Prescriptions for UK Patients Participating in Project Twenty21

Khiron Life Sciences Corp. (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), has announced the receipt of its first medical cannabis prescriptions for patients participating in Project Twenty21 in the United Kingdom (UK).

Khiron branded EU GMP medical cannabis is now available for prescription from doctors and clinics participating in Project Twenty21, Europe’s largest study of the effectiveness and tolerability of medical cannabis.

Khiron is the exclusive Latin American supplier to Project Twenty21, a leading UK registry study enrolling up to 20,000 patients by the end of 2021, to create the largest body of evidence in Europe for the effectiveness and tolerability of medical cannabis

Khiron has been actively preparing to supply Project Twenty21 since first announcing its participation in November 2019. The supply of EU GMP medical cannabis is fully supported by the Company’s global medical education team, led by Dr. Maria Fernanda Arboleda, International Director for Medical Services. Khiron will leverage educational materials and key learnings from the Company’s Colombian cannabis experience in making therapeutic recommendations for Project Twenty21.

Leading the project, Professor David Nutt from the UK’s leading independent scientific body Drug Science commented: “Khiron’s assistance in delivering Project Twenty21 will expand the formulary significantly. Our shared vision, accelerating access of medical cannabis to patients who need it the most, will be greatly enhanced by the support provided by the Khiron team.”

Tejinder Virk, President of Khiron Europe, commented: “The receipt of our first prescriptions in the UK is a testament to Khiron’s regulatory strengths and globally diversified supply chain strategy. We have the flexibility to source medical cannabis products from multiple countries, with an aim to optimize for quality, speed and economics. The implementation of virtual consultations in the UK and mail order fulfilment are also huge milestones, which remove friction for patients and help to drive positive health outcomes.”

Khiron has core operations in Latin America, along with activity in North America and Europe, and is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.

Project Twenty21 aims to enrol 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis – with an aim to demonstrate to policymakers that medical cannabis should be as widely available, and affordable, as other approved medicines for patients who would benefit from them.

Source | Khiron